Potential COVID-19 Products: Choosing the Right Path with FDA
Information is being shared by FDA in an ongoing fashion as they manage response to the current COVID-19 pandemic for ongoing and planned clinical research. If you are considering development of a product for treatment of COVID-19 or COVID-19-related indications, ensuring no time is wasted between idea and engaging FDA via the appropriate pathway with all the required information is essential. In this webinar, we’ll review the pathways you might consider, based on the development phase and overall goals for your product, and discuss the information and data necessary to help FDA expeditiously review your proposal and move it forward.
Kevin Barber, Ph.D.
Vice President, Regulatory Strategy & Submissions
Combining extensive strategic leadership, scientific knowledge, and regulatory expertise, Dr. Kevin Barber supports Rho’s clientele in the development…
Theresa Scocca, Ph.D.
A Research Scientist with almost a decade of experience in clinical research, Dr. Theresa Scocca currently serves as…